Ibrutinib case: US court denies Natco Pharma's partner Alvogen'sappeal
The suit is related to the proposed generic equivalents to Imbruvica tablets16-11-2022
16-11-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
loss of share certificates15-11-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q2 FY2023 Earnings call Audio Transcript11-11-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the Q2 2023 Financial Results11-11-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Paper publication - Un-audited Financial Results for the quarter and half year ended 30th September, 2022 & Notice of 2nd Interim Divided and Record Date11-11-2022
NATCO PHARMA LTD. - 524816 - Record Date For Payment Of 2Nd Interim Dividend
Record Date for payment of 2nd Interim Dividend is 22nd November 202210-11-2022
NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting held on 10-Nov-2022 to consider the unaudited financial Results for the quarter and half year ended 30th September 2022 and declared 2nd Interim Dividend of Rs.0.75 (i.e., 37.50%) per Equity shares of Rs.2/- each10-11-2022